Comment On: Brentuximab Vedotin-Related Neuropathy in a Patient with Gilbert Syndrome: Do Mutations of UGT1A1 Gene Affect Brentuximab Toxicity?

Pediatric Blood & CancerEarly View e30527 LETTER TO THE EDITOR Comment on: Brentuximab vedotin-related neuropathy in a patient with Gilbert syndrome: Do mutations of UGT1A1 gene affect brentuximab toxicity? Carla Marco, Carla Marco orcid.org/0009-0008-6330-1376 Neuro-Oncology Unit, Department of Neurology, Hospital Universitari de Bellvitge - Institut Català d'Oncologia, IDIBELL, L'Hospitalet de Llobregat, Barcelona, SpainSearch for more papers by this authorAriadna Padró-Miquel, Ariadna Padró-Miquel Molecular Genetics Unit, Clinical Laboratory, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet de Llobregat, Barcelona, SpainSearch for more papers by this authorEva Domingo-Domenech, Eva Domingo-Domenech orcid.org/0000-0001-8907-090X Department of Clinical Hematology, Institut Català d'Oncologia, Hospital Duran I Reynals, IDIBELL, L'Hospitalet de Llobregat, Barcelona, SpainSearch for more papers by this authorRoser Velasco, Corresponding Author Roser Velasco [email protected] orcid.org/0000-0003-3194-9406 Neuro-Oncology Unit, Department of Neurology, Hospital Universitari de Bellvitge - Institut Català d'Oncologia, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain Correspondence Roser Velasco, Unit of Neuro-Oncology, Catalan Institute of Oncology, University Hospital of Bellvitge, Avinguda de la Granvia de l'Hospitalet, 199-203, 08908 L'Hospitalet de Llobregat, Barcelona, Spain. Email: [email protected]Search for more papers by this author Carla Marco, Carla Marco orcid.org/0009-0008-6330-1376 Neuro-Oncology Unit, Department of Neurology, Hospital Universitari de Bellvitge - Institut Català d'Oncologia, IDIBELL, L'Hospitalet de Llobregat, Barcelona, SpainSearch for more papers by this authorAriadna Padró-Miquel, Ariadna Padró-Miquel Molecular Genetics Unit, Clinical Laboratory, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet de Llobregat, Barcelona, SpainSearch for more papers by this authorEva Domingo-Domenech, Eva Domingo-Domenech orcid.org/0000-0001-8907-090X Department of Clinical Hematology, Institut Català d'Oncologia, Hospital Duran I Reynals, IDIBELL, L'Hospitalet de Llobregat, Barcelona, SpainSearch for more papers by this authorRoser Velasco, Corresponding Author Roser Velasco [email protected] orcid.org/0000-0003-3194-9406 Neuro-Oncology Unit, Department of Neurology, Hospital Universitari de Bellvitge - Institut Català d'Oncologia, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain Correspondence Roser Velasco, Unit of Neuro-Oncology, Catalan Institute of Oncology, University Hospital of Bellvitge, Avinguda de la Granvia de l'Hospitalet, 199-203, 08908 L'Hospitalet de Llobregat, Barcelona, Spain. Email: [email protected]Search for more papers by this author First published: 26 June 2023 https://doi.org/10.1002/pbc.30527Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Diebert N, Baker K, Fernandez K. Brentuximab vedotin related neuropathy in a patient with Gilbert syndrome: Do mutations of UGT1A1 gene affect brentuximab toxicity? Pediatr Blood Cancer. 2022; 69(6):e29444. doi:10.1002/pbc.29444 2Hsieh TY, Shiu TY, Huang SM, et al. Molecular pathogenesis of Gilbert syndrome: Decreased TATA-binding protein binding affinity of UGT1A1 gene promoter. Pharmacogenet Genomics. 2007; 17(4): 229-236. doi:10.1097/FPC.0b013e328012d0da 3Velasco R, Domingo-Domenech E, Sureda A. Brentuximab-induced peripheral neurotoxicity: A multidisciplinary approach to manage an emerging challenge in Hodgkin lymphoma therapy. Cancers (Basel). 2021; 13(23): 6125. doi:10.3390/cancers13236125 4Gammal RS, Court MH, Haidar CE, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for UGT1A1 and atazanavir prescribing. Clin Pharmacol Ther. 2016; 99(4): 363-369. doi:10.1002/cpt.269 Early ViewOnline Version of Record before inclusion in an issuee30527 ReferencesRelatedInformation